The chronic bronchitis phenotype in chronic obstructive pulmonary disease: Features and implications

Current Opinion in Pulmonary Medicine

Volumn 21, Issue 2, 2015, Pages 133-141

  Kim, Victor ^a   Criner, Gerard J ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

airway disease; chronic bronchitis; chronic obstructive pulmonary disease; genetics; N Acetylcysteine

Indexed keywords

ANTIOXIDANT; MACROLIDE; PHOSPHODIESTERASE IV INHIBITOR;

CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RESPIRATORY TRACT DISEASE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE EXACERBATION; ENVIRONMENTAL FACTOR; EPIDEMIC; GENETIC ASSOCIATION; HIGH RISK POPULATION; HUMAN; LUNG FUNCTION; MORBIDITY; MORTALITY; PHENOTYPE; QUALITY OF LIFE; REVIEW; THORAX RADIOGRAPHY; BRONCHITIS, CHRONIC; GENETICS; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTOR;

BRONCHITIS, CHRONIC; HUMANS; PHENOTYPE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RISK FACTORS;

EID: 84922400968     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000145     Document Type: Review

References (83)

1. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187:347-365
2. Ferris BG. EpiDemiology standardization project (American Thoracic Society). Am Rev Respir Dis 1978; 118 (6 Pt 2):1-120
3. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 Decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996; 153:1530-1535
4. Pelkonen M, Notkola IL, Nissinen A, et al. Thirty-year cumulative inciDence of chronic bronchitis and COPD in relation to 30-year pulmonary function and 40-year mortality: a follow-up in middle-Aged rural men. Chest 2006; 130:1129-1137
5. Guerra S, Sherrill DL, Venker C, et al. Chronic bronchitis before age 50 years predicts inciDent airflow limitation and mortality risk. Thorax 2009; 64:894-900
6. Kim V, Han MK, Vance GB, et al. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene study. Chest 2011; 140:626-633
7. Burgel PR. Chronic cough and sputum production: a clinical COPD phenotype? Eur Respir J 2012; 40:4-6
8. Lee JH, Cho MH, McDonald ML, et al. Phenotypic and genetic heterogeneity among subjects with mild airflow obstruction in COPDGene. Respir Med 2014; 108:1469-1480
9. Lange P, Groth S, Nyboe J, et al. Chronic obstructive lung disease in Copenhagen: Cross-sectional epiDemiological aspects. J Intern Med 1989; 226:25-32
10. Pallasaho P, Lundback B, Laspa SL, et al. Increasing prevalence of asthma but not of chronic bronchitis in Finland? Report from the FinEsS-Helsinki study. Respir Med 1999; 93:798-809
11. Von Hertzen L, Reunanen A, Impivaara O, et al. Airway obstruction in relation to symptoms in chronic respiratory disease-A nationally representative population study. Respir Med 2000; 94:356-363
12. Cerveri I, Accordini S, Verlato G, et al. Variations in the prevalence across countries of chronic bronchitis and smoking habits in young adults. Eur Respir J 2001; 18:85-92
13. Janson C, Chinn S, Jarvis D, Burney P. Determinants of cough in young adults participating in the European Community Respiratory Health Survey. Eur Respir J 2001; 18:647-654
14. Huchon GJ, Vergnenegre A, Neukirch F, et al. Chronic bronchitis among French adults: high prevalence and unDerdiagnosis. Eur Respir J 2002; 20:806-812
15. Lundback B, Lindberg A, Lindstrom M, et al. Not 15 but 50% of smokers Develop COPD? Report from the obstructive lung disease in northern SweDen studies. Respir Med 2003; 97:115-122
16. Miravitlles M, De La Roza C, Morera J, et al. Chronic respiratory symptoms, spirometry and knowledge of COPD among general population. Respir Med 2006; 100:1973-1980
17. De Marco R, Accordini S, Cerveri I, et al. InciDence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. Am J Respir Crit Care Med 2007; 175:32-39
18. Miravitlles M, Soriano JB, Garcia-Rio F, et al. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities. Thorax 2009; 64:863-868
19. Harmsen L, Thomsen SF, Ingebrigtsen T, et al. Chronic mucus hypersecretion: Prevalence and risk factors in younger individuals. Int J Tuberc Lung Dis 2010; 14:1052-1058
20. Martinez CH, Kim V, Chen Y, et al. The clinical impact of nonobstructive chronic bronchitis in current and former smokers. Respir Med 2014; 108:491-499
21. Sobradillo V, Miravitlles M, Jimenez CA, et al. EpiDemiological study of chronic obstructive pulmonary disease in Spain (IBERPOC): Prevalence of chronic respiratory symptoms and airflow limitation. Arch Bronconeumol 1999; 35:159-166
22. Miravitlles M. Cough and sputum production as risk factors for poor outcomes in patients with COPD. Respir Med 2011; 105:1118-1128
23. American Lung Association. Trends in COPD (chronic bronchitis and emphysema): morbidity and mortality. 2013; Accessed at www.lung.org/findingcures/our-research/trend-reports/copd-trend-report.pdf
24. Burgel PR, Nesme-Meyer P, Chanez P, et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 2009; 135:975-982
25. Agusti A, Calverley PM, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010; 11:122
26. De Oca MM, Halbert RJ, Lopez MV, et al. The chronic bronchitis phenotype in subjects with and without COPD: The PLATINO study. Eur Respir J 2012; 40:28-36
27. Kim V, Davey A, Comellas AP, et al. Clinical and computed tomographic predictors of chronic bronchitis in COPD: a cross sectional analysis of the COPDGene study. Respir Res 2014; 15:52
28. Lange P, Nyboe J, Appleyard M, et al. Relation of ventilatory impairment and of chronic mucus hypersecretion to mortality from obstructive lung disease and from all causes. Thorax 1990; 45:579-585
29. Speizer FE, Fay ME, Dockery DW, Ferris BG Jr. Chronic obstructive pulmonary disease mortality in six U.S. cities. Am Rev Respir Dis 1989; 140 (3 Pt 2):S49-55
30. Lu M, Yao W, Zhong N, et al. Chronic obstructive pulmonary disease in the absence of chronic bronchitis in China. Respirology 2010; 15:1072-1078
31. Watson L, Schouten JP, Lofdahl CG, et al. Predictors of COPD symptoms: does the sex of the patient matter? Eur Respir J 2006; 28:311-318
32. Regan EA, Hokanson JE, Murphy JR, et al. Genetic epiDemiology of COPD (COPDGene) study Design. COPD 2010; 7:32-43
33. Ferre A, Fuhrman C, Zureik M, et al. Chronic bronchitis in the general population: Influence of age, genDer and socio-economic conditions. Respir Med 2012; 106:467-471
34. Forey BA, Thornton AJ, Lee PN. Systematic review with meta-Analysis of the epiDemiological eviDence relating smoking to COPD, chronic bronchitis and emphysema. BMC Pulm Med 2011; 11:36
35. Dijkstra AE, De Jong K, Boezen HM, et al. Risk factors for chronic mucus hypersecretion in individuals with and without COPD: Influence of smoking and job exposure on CMH. Occup Environ Med 2014; 71:346-352
36. Sumner H, Woodcock A, Kolsum U, et al. Predictors of objective cough frequency in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187:943-949
37. Accordini S, Corsico AG, Cerveri I, et al. Diverging trends of chronic bronchitis and smoking habits between 1998 and 2010. Respir Res 2013; 14:16
38. Rodriguez E, Ferrer J, Zock JP, et al. Lifetime occupational exposure to dusts, gases and fumes is associated with bronchitis symptoms and higher diffusion capacity in COPD patients. PLoS One 2014; 9:e88426
39. Marchetti N, Garshick E, Kinney GL, et al. Association between occupational exposure and lung function, respiratory symptoms and high resolution CT imaging in COPDGene. Am J Respir Crit Care Med 2014; 190:756-762
40. Perez-Padilla R, Ramirez-Venegas A, Sansores R. Clinical characteristics of patients with biomass smoke-Associated COPD and chronic bronchitis, 2004-2014. J COPD Found 2014; 1:23-32
41. Camp PG, Ramirez-Venegas A, Sansores RH, et al. COPD phenotypes in biomass smoke-versus tobacco smoke-exposed Mexican women. Eur Respir J 2014; 43:725-734
42. Gonzalez-Garcia M, Maldonado Gomez D, Torres-Duque CA, et al. Tomographic and functional findings in severe COPD: Comparison between the wood smoke-related and smoking-related disease. J Bras Pneumol 2013; 39:147-154
43. Moreira MA, Barbosa MA, Queiroz MC, et al. Pulmonary changes on HRCT scans in nonsmoking females with COPD due to wood smoke exposure. J Bras Pneumol 2013; 39:155-163
44. Committee of the Environmental and Occupational Health Assembly of the American Thoracic Society. Health effects of outdoor air pollution. Am J Respir Crit Care Med 1996; 153:3-50
45. Pfister GG, Walters S, Lamarque JF, et al. Projections of future summertime ozone over the U.S. Am Geophys Union 2014; 119: 5559-5582
46. Kousha T, Rowe BH. Ambient ozone and emergency Department visits due to lower respiratory condition. Int J Occup Med Environ Health 2014; 27:50-59
47. Atkinson RW, Kang S, AnDerson HR, et al. EpiDemiological time series studies of PM2.5 and daily mortality and hospital admissions: a systematic review and meta-Analysis. Thorax 2014; 69:660-665
48. DadVand P, Nieuwenhuijsen MJ, Agust A, et al. Air pollution and biomarkers of systemic inflammation and tissue repair in COPD patients. Eur Respir J 2014; 44:603-613
49. Kim V, Martinez FJ, Han MK, Criner GJ. Clinical and radiographic characteristics of COPD with and without chronic bronchitis [abstract]. Am J Respir Crit Care Med 2014; A5931
50. Cai Y, Schikowski T, Adam M, et al. Cross-sectional associations between air pollution and chronic bronchitis: an ESCAPE meta-Analysis across five cohorts. Thorax 2014; 69:1005-1014
51. Jamieson DB, Matsui EC, Belli A, et al. Effects of allergic phenotype on respiratory symptoms and exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 188:187-192
52. Meteran H, Backer V, Kyvik KO, et al. Heredity of chronic bronchitis: a registrybased twin study. Respir Med 2014; 108:1321-1326
53. Dijkstra AE, Smolonska J, Van Den Berge M, et al. Susceptibility to chronic mucus hypersecretion: a genome wiDe association study. PLoS One 2014; 9:e91621
54. Lee J, Cho MH, Hersh CP, et al. Genetic susceptibility for chronic bronchitis in chronic obstructive pulmonary disease. Respir Res 2014; 15:113
55. Orlandi I, Moroni C, Camiciottoli G, et al. Chronic obstructive pulmonary disease: thin-section CT measurement of airway wall thickness and lung attenuation. Radiology 2005; 234:604-610
56. Camiciottoli G, Bigazzi F, Paoletti M, et al. Pulmonary function and sputum characteristics predict computed tomography phenotype and severity of COPD. Eur Respir J 2013; 42:626-635
57. Sherman CB, Xu X, Speizer FE, et al. Longitudinal lung function Decline in subjects with respiratory symptoms. Am Rev Respir Dis 1992; 146:855-859
58. Lindberg A, Eriksson B, Larsson LG, et al. Seven-year cumulative inciDence of COPD in an age-stratified general population sample. Chest 2006; 129:879-885
59. Corhay JL, Vincken W, Schlesser M, et al. Chronic bronchitis in COPD patients is associated with increased risk of exacerbations: a cross-sectional multicentre study. Int J Clin Pract 2013; 67:1294-1301
60. Annesi I, Kauffmann F. Is respiratory mucus hypersecretion really an innocent disorDer? A 22-year mortality survey of 1, 061 working men. Am Rev Respir Dis 1986; 134:688-693
61. Tockman MS, Comstock GW. Respiratory risk factors and mortality: longitudinal studies in Washington county, Maryland. Am Rev Respir Dis 1989; 140 (3 Pt 2):S56-63
62. Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD and Death from pulmonary infection. Eur Respir J 1995; 8:1333-1338
63. Mannino DM, Buist AS, Petty TL, et al. Lung function and mortality in the United States: data from the first National Health and Nutrition Examination Survey follow up study. Thorax 2003; 58:388-393
64. Ramos FL, Krahnke JS, Kim V. Clinical issues of mucus accumulation in COPD. Int J Chron Obstruct Pulmon Dis 2014; 9:139-150
65. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363:1128-1138
66. Tan WC, Bourbeau J, HernanDez P, et al. Exacerbation-like respiratory symptoms in individuals without chronic obstructive pulmonary disease: results from a population-based study. Thorax 2014; 69:709-717
67. Martinez C, Chen Y, Kazerooni E, et al. Nonobstructive chronic bronchitis in the COPDGene cohort [abstract]. Am J Respir Crit Care Med 2012; A6622
68. Bowler RP, Kim V, Regan E, et al. Prediction of acute respiratory disease in current and former smokers with and without COPD. Chest 2014; 146:941-950
69. Han MK, Kim V, Martinez C, et al. Significance of chronic bronchitis in the COPD CRN azithromycin in COPD study [abstract]. Am J Respir Crit Care Med 2012; A3736
70. Kim V, Sternberg AL, Washko G, et al. Severe chronic bronchitis in adVanced emphysema increases mortality and hospitalizations. COPD 2013; 10:667-678
71. Kim V, Criner GJ. Chronic bronchitis and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187:228-237
72. Abudagga A, Sun SX, Tan H, Solem CT. Exacerbations among chronic bronchitis patients treated with maintenance medications from a US managed care population: An administrative claims data analysis. Int J Chron Obstruct Pulmon Dis 2013; 8:175-185
73. Tarran R, Sabater JR, Clarke TC, et al. Nonantibiotic macroliDes prevent human neutrophil elastase-induced mucus stasis and airway surface liquid volume Depletion. Am J Physiol Lung Cell Mol Physiol 2013; 304:L746-L756
74. Seemungal TA, Wilkinson TM, Hurst JR, et al. Long-term erythromycin therapy is associated with Decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008; 178:1139-1147
75. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011; 365:689-698
76. HanMK, Tayob N, Murray S, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med 2014; 189:1503-1508
77. Dransfield MT, Wilhelm AM, Flanagan B, et al. Acquired cystic fibrosis transmembrane conductance regulator dysfunction in the lower airways in COPD. Chest 2013; 144:498-506
78. Lambert JA, Raju SV, Tang LP, et al. Cystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitis. Am J Respir Cell Mol Biol 2014; 50:549-558
79. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moDerateto-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomised clinical trials. Lancet 2009; 374:695-703
80. Decramer M, Rutten-Van Molken M, Dekhuijzen PN, et al. Effects of Nacetylcysteine on outcomes in chronic obstructive pulmonary disease (bronchitis randomized on NAC cost-utility study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005; 365:1552-1560
81. Zheng JP, Kang J, Huang SG, et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE study): a randomised placebo-controlled study. Lancet 2008; 371:2013-2018
82. Tse HN, Raiteri L, Wong KY, et al. High-dose N-Acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study. Chest 2013; 144:106-118
83. Zheng JP, Wen FQ, Bai CX, et al. Twice daily N-Acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med 2014; 2:187-194